With nearly 10% of global population aged 65+, it is estimated this population segment will comprise more than 1.6bn people by 2050. Given this trend, which will require increasing levels of treatment for chronic diseases, the pharmaceutical and medical technology sectors have particularly attractive return profiles.
Our pharmaceutical and medical technology investments have a low correlation with Mubadala’s wider portfolio and our current priority sub-sectors include:
- • Pharmaceuticals, with a focus on the rapidly-growing biologics and complex small molecules segments
- • Medical Technology, with a focus on orthopedic, cardiovascular, chronic care, and home health solutions
- • Healthcare IT and Digital Health, given the growing trends of digitization, remote care, and big data & analytics within healthcare
- • Animal Health, whose sustained growth levels are driven by rising pet adoption and the importance of pet care to many global households, as well as continued protein consumption globally
Mubadala led Outset Medical’s US$132 million series D fundraising round, becoming one of the leading investors in the manufacturer of innovative home dialysis technology
The global healthcare market is currently $8.6 trillion and is estimated to grow to $10.1 trillion by 2024